PEI MELINDA LITHERLAND 4

What Happened

• Melinda Litherland, a director of Rapid Micro Biosystems (RPID), received equity awards on 2026-05-21: 19,300 restricted stock units (RSUs) and a 38,700-share derivative award (an option). Both entries show an acquisition price of $0.00 (no cash paid at grant). The filing was submitted on 2026-05-26.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (filed 5 days after the transaction — later than the usual 2-business-day Form 4 deadline).
• Grants: 19,300 RSUs (reported as A) and 38,700 derivative award (reported as A, footnote indicates this is an option).
• Reported purchase price: $0.00 for both awards (typical for equity grants).
• Vesting/exercise conditions: Both awards vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the day before the next annual meeting, provided the reporting person remains in continuous service (footnotes F1 and F2). Footnote F2 specifies the derivative is an option that will vest and become exercisable on that schedule.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: appears late relative to the typical 2-business-day requirement (filed 5 days after the reported transaction).

Context

• These are standard compensation grants to a director (not an open-market purchase or sale). RSUs and option grants are common for aligning director incentives and do not by themselves indicate a buy/sell decision by the insider. Because the option vests in the future, there was no immediate exercise or sale of shares reported.